The Global Lysosomal storage disorder drugs market size stood at USD 7.2 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Lysosomal Storage Diseases (LSDs) are inherited disorders caused due to lack of specific enzymes that break down certain lipids or carbohydrates in the body cells. Gaucher disease is one of the most common LSDs. Fabry disease, Niemann-Pick disease, Hunter syndrome, Glycogen storage disease II (Pompe disease), and Tay-Sachs disease are some of the other examples of LSDs
Factors driving the global demand for lysosomal storage diseases therapeutics include a faster uptake and faster market access, premium product pricing, and increasing focus of pharmaceutical companies in the research and development of drugs for the treatment of rare diseases. However, heterogeneity of the disease leading to underdiagnoses of lysosomal storage diseases, lack of treatment options, and high cost of treatment are factors likely to hamper the growth of the global lysosomal storage diseases therapeutics market over the forecast period